Tome Biosciences has acquired Replace Therapeutics, a biotechnology company focused on developing a novel programmable genomic integration method capable of inserting and deleting small DNA sequences, for a total consideration of $185 million. Berkeley, California-based Replace Therapeutics was represented by a Wilson Sonsini Goodrich & Rosati team including partners Jason Breen and James Huie. Counsel information for Tome Biosciences, which is based in Watertown, Massachusetts, was not immediately available.
Biotech & Pharmaceuticals
January 04, 2024, 11:21 AM